A disease known as benign prostatic hyperplasia may produce similar symptoms. It can worsen symptoms in men with benign prostatic hyperplasia. Benign prostatic hyperplasia is an age-related disease. It is used to treat benign prostatic hyperplasia (BPH). Dutasteride is used for treating benign prostatic hyperplasia (BPH); colloquially known as an "enlarged prostate". Finasteride reduces prostate volume by 20 to 30% in men with benign prostatic hyperplasia. Inhibition of myostatin leads to muscle hyperplasia and hypertrophy. There is only one compelling indication for alpha blockers, which is for benign prostatic hyperplasia. This action is associated with an increased incidence of endometrial hyperplasia and carcinoma. This condition has been defined as giant prostatic hyperplasia (GPH). Conditions such as congenital adrenal hyperplasia virilize genetic females due to a 21-hydroxylase deficiency. Follicular hyperplasia is a type of lymphoid hyperplasia. The most common form of congenital adrenal hyperplasia is due to 21-hydroxylase deficiency. Dydrogesterone effectively protects against the ontogenesis of endometrial hyperplasia. This causes endothelial hyperplasia, abnormal junctions, and diabetic retinopathy.